Oxygen Biotech

Oxygen Biotech is at the forefront of pharmaceutical innovation, dedicated to developing transformative treatments for severe COVID-19 (SARS-CoV-2), Acute Respiratory Distress Syndrome (ARDS), and post-COVID Syndrome (PCS). Located in Praha 2, Praha, with an additional office at 108 W 13th St, Wilmington, Delaware, Oxygen Biotech's flagship product, BAZE-X1, represents a groundbreaking approach to these complex conditions. This patented drug boasts a unique “dual-mode” action, combining antiviral and immunomodulatory properties to address the underlying causes of these debilitating illnesses.

Built on a foundation of rigorous scientific research and collaborative partnerships, Oxygen Biotech leverages the expertise of leading Czech scientists, clinicians, and internationally recognized specialists from both the European Union and the United States. The company’s origins are deeply rooted in the renowned BIOCEV research organization, a collaborative effort between the Czech Academy of Sciences and Charles University in Prague, reflecting a commitment to excellence in scientific discovery. Oxygen Biotech is committed to advancing medical breakthroughs and improving patient outcomes through cutting-edge pharmaceutical solutions.

Oxygen Biotech's mission is to deliver innovative therapies that significantly enhance the quality of life for individuals affected by these critical health challenges. With a focus on scientific rigor, collaborative research, and patient-centric care, Oxygen Biotech is poised to make a lasting impact on the treatment of severe COVID-19, ARDS, and post-COVID Syndrome. Our state-of-the-art facilities at Italská 67, Churchill I., Praha 2, Praha 13000, CZ, are dedicated to the continued development and refinement of BAZE-X1 and future therapeutic advancements. We invite you to connect with our management team to create a customized and exclusive company showcase and product listing on our platform to further expand your reach and impact.